Phergain study

Author: xicj

August undefined, 2024

WebAbstract. Disrupted protein folding or decreased protein stability can lead to the accumulation of (partially) un- or misfolded proteins, which ultimately cause the … WebJun 3, 2024 · PHERGain study Early results have shown that interim PET seems to be surrogate marker for pCR and the BCS rates are not compromised in the chemo free strategy and also with a favourable toxicity profile. Hence, a PET-adapted approach seems to be a promising modality for escalation, de-escalation strategy.

Three-Year Follow-up of Neoadjuvant Chemotherapy With or …

WebAll patients who received at least one cycle of therapy were assessed for safety. This trial is registered with ClinicalTrials.gov, number NCT02530424. The trial is ongoing and two further cohorts are being enrolled. Findings: Thus, 35 patients were included in safety analyses and 30 were assessed for the primary and secondary endpoints. WebFeb 9, 2024 · • The PHERGain II clinical trial aims to demonstrate the viability of a non-chemotherapy alternative for treating those patients who can achieve a similar response … psychological lines are:

Chemotherapy-free Trastuzumab and Pertuzumab in …

WebJun 4, 2024 · The study authors noted that neoadjuvant dual blockade of HER2 results in pathologic complete response (pCR) rates of up to 36.3%, which provides rationale for … WebJan 6, 2024 · The PHERGain study evaluating de-escalating neoadjuvant therapy in patients with HER2+ breast cancer demonstrated a pCR rate of 32.3% in patients with ER+/HER2+ early breast cancer treated with ... WebMay 1, 2024 · In the recently published PHERGAIN study [36], early metabolic response by FDG-PET showed promise to identify patients who will benefit from anti-HER2 therapy and, therefore, can be spared of ... psychological lines art

18FDG-PET May Identify Patients With HER2-Positive Early Breast …

Chemotherapy de-escalation using an 18F-FDG-PET-based

WebOct 27, 2024 · The study includes 376 women with a type of breast cancer called HER2-positive breast cancer that can be removed by surgery. In the study, researchers wanted … WebMay 29, 2024 · PHERGAIN In another trial, researchers showed that early evaluation of metabolic response using 18 F-FDG PET/CT could help identify patients who will develop a pCR to dual HER2 blockade alone, potentially … hospitals in south wales ukWebFeb 1, 2024 · Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) The safety and scientific … hospitals in spintex road

"WebA study version is represented by a row in the table. Select two study versions to compare. One each from columns A and B. ... (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study : Secondary IDs: 2016-002676-27 [EudraCT Number] Study Status. Record Verification: July 2024 : Overall Status: Active, … " - Phergain study

Phergain study

WebMay 18, 2024 · PHERGain was a strategy-based study with a unique design. Previous trials of de-escalation strategies in HER2-positive, early-stage breast cancer have highlighted the importance of establishing innovative clinical designs, together with optimal selection of … WebFeb 3, 2024 · PHERGain-2: a study of a new therapeutic strategy to avoid chemotherapy in breast cancer patients. Updated: Dec 7, 2024. We have initiated the PHERGain-2 clinical …

Did you know?

WebJun 19, 2024 · The PHERGAIN study is evaluating the use of positron emission tomography (PET) imaging during neoadjuvant therapy to monitor tumor response in patients with HER2-positive breast cancer. In preliminary results, investigators reported that patients whose PET scan showed positive response to the treatment had pathological complete response. WebOct 27, 2024 · The PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 ( …

WebFeb 10, 2024 · The PHERGain II study's goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without … WebThe PHERGain study: A.3.2: Name or abbreviated title of the trial where available: PHERGain: A.4.1: Sponsor's protocol code number: MedOPP096-MO39229: A.7: ... The end of study will be three years from surgery (for cohorts A and B and for cohort C only if surgery is performed), up to three years from randomization of the last patient (for ...

WebThe PHERGain study, can you speak to that? Erika P. Hamilton (11:47): PHERGain was a very complicated study. Essentially what they did is they used antibody HER2 treatment and dropped the chemotherapy out for some patients, and other patients got chemotherapy with HER2 treatment. WebSep 8, 2024 · In the PHERGAIN trial, researchers showed that early evaluation of metabolic response using 18F-FDG PET/CT could help identify patients who will develop a pathologic complete response (pCR) to dual HER2 blockade alone, potentially allowing them to avoid chemotherapy [1].

WebNational Center for Biotechnology Information

WebJun 29, 2024 · PHERGain met its first co-primary endpoint by showing that 37.9% of patients who received dual HER2 blockade with trastuzumab and pertuzumab, with or without endocrine therapy, and who were [18FDG-PET] responders achieved a pathological complete response in the breast and axilla and, accordingly, might avoid chemotherapy as part of … psychological lines art definitionWebthe phergain study CLINICAL TRIAL DETAILS THE STUDY ASSESS THE EARLY METABOLIC EFFECTS OF NEOADJUVANT TREATMENT WITH TRASTUZUMAB AND PERTUZUMAB (± … psychological listeningWebEssais cliniques pour trastuzumab emtansin. Registre des essais cliniques. ICH GCP. psychological linguisticsWebFeb 24, 2024 · PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer. The PHERGain II trial will investigate the treatment … psychological literacyWebFeb 15, 2024 · PHERGain-2 study is an additional step forward and aims to assess the feasibility of chemotherapy de-escalation with neoadjuvant HP followed by adjuvant HP or T-DM1 using a pathological response-adapted strategy in low-risk HER2-positive early breast cancer pts. Trial Design: PHERGain-2 is a multicenter, open-label, non-comparative, phase … psychological lines in artWebApr 10, 2024 · Background: Anticancer treatments are improving the prognosis of patients fighting cancer. However, anticancer treatments may also increase the cardiovascular (CV) risk by increasing metabolic disorders. Atherosclerosis and atherothrombosis related to anticancer treatments may lead to ischemic heart disease (IHD), while direct cardiac … hospitals in st albansWebOct 27, 2024 · This is a summary of a publication about the PHERGain study, which was published in The Lancet Oncology in May 2024. The study includes 376 women with a type of breast cancer called HER2-positive ... psychological literary approach